Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy talks about blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). Blinatumomab targets CD90 and works differently than inotuzumab, which targets CD22. According to Prof Martinelli, blinatumomab may be an especially promising treatment option for elderly patients who are not eligible for a transplant.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.